TMS for ADHD: Promising or Premature?

TMS for ADHD is premature as a treatment and promising only as a research question. No TMS device is FDA-cleared for ADHD, so any use outside a study is off-label, and the controlled trials disagree: a 2024 meta-analysis of six sham-controlled trials found no overall benefit, while a 2025 meta-analysis of eight studies reported significant improvement.

The fairest reading is that a narrow version of the idea, stimulating the right prefrontal cortex in adults, deserves a properly sized trial. It does not yet deserve a place in routine ADHD care, where established medication already benefits most patients.

What FDA has and has not cleared

FDA's TMS clearances cover major depression, OCD as an adjunct, short-term smoking cessation, migraine and, since June 2026, adjunct treatment of adult PTSD with one specific system. ADHD is not on that list.

A different kind of device is. In April 2019 FDA authorized the Monarch external Trigeminal Nerve Stimulation (eTNS) System, a prescription device that sends low-level electrical pulses through a patch on the forehead during sleep, for children aged 7 to 12 who are not taking prescription ADHD medication. It is not TMS, but it is often confused with it, and it shows the kind of evidence FDA wanted for a first ADHD device: a randomized, placebo-device trial in 62 children.

The trials, side by side

Two features of this table matter more than any single result. The samples are small: even the larger meta-analysis pools only 325 patients across eight studies. And the positive signals cluster around one target, the right prefrontal cortex, while bilateral stimulation came up empty.

Why the results disagree

When two meta-analyses published a year apart reach different conclusions, a common explanation is that they included different studies. Analyses limited to sham-controlled trials, as in 2024, can show smaller effects than collections that admit open-label or less rigorously blinded work. Several other factors pull results apart:

• Different targets. Right prefrontal, left prefrontal and bilateral protocols are not the same treatment, and pooling them dilutes any real effect.
• Different outcomes. Some trials measure self-reported symptoms, others computerized attention tests. The 2024 analysis found benefit for inattention specifically.
• Different patients. Medication-free adults, adults on stimulants and children respond to brain stimulation in different ways, and the trials mix them.
• Industry ties. The positive 2020 pilot was run by researchers with financial and consulting links to a deep TMS manufacturer, which the paper discloses. That does not invalidate the result, but it raises the bar for independent replication.

The biomarker angle

The Alyagon pilot reported that an EEG pattern recorded during the first session correlated closely with how much each patient improved. If that held up, it would let clinicians predict who might benefit before committing to weeks of sessions. It comes from a group of 15 people who received real treatment, so it is a hypothesis, not a test. The broader search for response predictors in depression is covered in who responds to TMS, and the targeting question in finding the target.

What a convincing trial would need

The depression evidence for TMS became persuasive only after large, multicenter, sham-controlled trials with prespecified outcomes. ADHD research has not reached that stage. A trial that would change practice would need several hundred participants across more than one site, a single prespecified target and protocol (most plausibly right prefrontal), a credible sham that blinds both patients and raters, and outcomes that matter in daily life, such as work or school functioning, not only rating scales. It would also need follow-up of months rather than weeks, because a benefit that fades soon after the last session would have limited practical value. Until that evidence exists, the honest description of TMS for ADHD is "under investigation". The landmark trials that set this bar for depression are summarized in TMS research: the landmark trials.

Children and teenagers

The adolescent TMS clearances are for major depression in people aged 15 to 21, given as an adjunct to other treatment. They say nothing about ADHD. The two individual trials above were in adults, and a family considering TMS for a child's ADHD would be relying on limited evidence. A careful ADHD diagnosis and established treatment come first; if depression is also present, the teen TMS evidence is discussed in TMS for teens and young adults.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Where ADHD and depression overlap

Adults with ADHD often also have depression, and the symptoms overlap: poor concentration, low motivation and disorganization appear in both. If someone has major depression that has not improved with medication, TMS for the depression is an on-label use even if ADHD is present.

The reverse error also happens. Attention problems that began in adulthood may reflect depression, anxiety, sleep problems, trauma or bipolar disorder rather than ADHD, which is why an evaluation should rule out conditions that mimic ADHD and consider bipolar disorder versus ADHD.

Safety and medications

The safety picture for TMS in adults with ADHD appears similar to TMS generally; the 2020 pilot reported that real treatment was safe. On medications, the 2021 IFCN expert guideline says the earlier caution about drugs that lower seizure threshold is "no longer" supported by the available data, while still recommending that all concurrent drugs and other risk factors be documented. Sleep deprivation is one such factor. The full risk picture is in TMS safety and seizure risk, and how TMS interacts with ongoing prescriptions in combining TMS with medication.

Cost and coverage

The insurer policies reviewed for this guide do not cover TMS for ADHD. EmblemHealth, for example, marks TMS for indications other than depression as not covered, and New York Medicare's TMS policy is limited to adults with major depressive disorder. Anyone offered TMS for ADHD outside a trial should expect to pay out of pocket for an unproven use.

Questions to ask if TMS for ADHD is offered

1. Is this a registered clinical trial, or a clinical service? If a service, what evidence supports this exact protocol?
2. Which target and frequency will be used, and has that combination been tested against sham in ADHD?
3. How will improvement be measured, by whom, and at what point would treatment stop?
4. Has my diagnosis been confirmed, and have depression, sleep and anxiety been assessed?
5. What will it cost, and is any of it covered?

The bottom line

TMS for ADHD is a reasonable research direction with one encouraging adult pilot, one negative trial and conflicting meta-analyses. It is not ready to replace or supplement standard care outside a study. People with ADHD who are frustrated with treatment usually have better-proven options to try first, starting with a review of the diagnosis and the current plan, as described in when ADHD medication stops working and on the ADHD psychiatry page.

For the rest of the evidence on TMS, see the TMS physician's guide; for how a TMS evaluation for depression works, see the TMS service page. Related research-stage topics include TMS and autism.

Frequently asked questions

Is TMS FDA-cleared for ADHD?

No. TMS is cleared for depression, OCD (as an adjunct), smoking cessation, migraine and, with one system, adjunct PTSD treatment. The only FDA-authorized ADHD device is a different technology, external trigeminal nerve stimulation, for children aged 7 to 12.

Is eTNS the same as TMS?

No. External trigeminal nerve stimulation uses a small electrical current through a forehead patch during sleep. TMS uses a magnetic coil held against the scalp, usually in a clinic.

Could TMS help my focus if I have depression and ADHD?

If you have major depression that has not responded to medication, TMS for depression is an on-label option and concentration may improve when depression lifts. It is not proven to treat ADHD itself.

Can I stay on stimulant medication during TMS?

That is a question for the treating psychiatrist. The 2021 international safety guideline no longer advises general caution about medications that lower seizure threshold but recommends documenting every drug a patient takes.

Are there ADHD TMS trials I could join?

Trials open and close often. ClinicalTrials.gov lists current studies; check that any trial is sham-controlled and approved by an ethics board.

Sources

1. A meta-analysis of randomized sham-controlled trials of repetitive transcranial magnetic stimulation for attention deficit/hyperactivity disorder. Revista Brasileira de Psiquiatria, 2024. europepmc.org
2. Efficacy and Safety of Transcranial Magnetic Stimulation for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-Analysis. Brain and Behavior, 2025. europepmc.org
3. Alleviation of ADHD symptoms by non-invasive right prefrontal stimulation is correlated with EEG activity. NeuroImage: Clinical, 2020. pubmed.ncbi.nlm.nih.gov
4. Randomised sham-controlled study of high-frequency bilateral deep transcranial magnetic stimulation (dTMS) to treat adult attention hyperactive disorder (ADHD): Negative results. World Journal of Biological Psychiatry, 2018. pubmed.ncbi.nlm.nih.gov
5. FDA permits marketing of first medical device for treatment of ADHD. U.S. FDA, 2019. fda.gov
6. De Novo Classification Request DEN180041: Monarch eTNS System. U.S. FDA, 2019. accessdata.fda.gov
7. 21 CFR 882.5805 and 882.5802 (TMS device regulations). eCFR, 2026. ecfr.gov
8. 510(k) K200957 and K203616: BrainsWay Deep TMS for smoking cessation. U.S. FDA, 2021. accessdata.fda.gov
9. 510(k) K260402: MeRT System. U.S. FDA, 2026. accessdata.fda.gov
10. De Novo Classification Request DEN130022: Cerena Transcranial Magnetic Stimulator. U.S. FDA, 2013. accessdata.fda.gov
11. 510(k) Premarket Notification records for adolescent MDD labels (K231926 and others). U.S. FDA, 2026. accessdata.fda.gov
12. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
13. EmblemHealth Medical Technology Database. EmblemHealth, 2025. emblemhealth.com
14. LCD L33398 Transcranial Magnetic Stimulation (version 40). CMS Medicare Coverage Database, 2026. cms.gov

Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.